Many open form (OF) structures of drug targets were obtained a posteriori by analysis of cocrystals with inhibitors. Therefore, obtaining the OF structure of a drug target a priori will accelerate development of potent inhibitors. In addition to its small active site, Trypanosoma cruzi dihydroorotate dehydrogenase (TcDHODH) is fully functional in its monomeric form, making drug design approaches targeting the active site and protein-protein interactions unrealistic. Therefore, a novel a priori approach was developed to determination the TcDHODH active site in OF. This approach consists of generating an "OF inducer" (predicted in silico) to bind the target and cause steric repulsion with flexible regions proximal to the active site that force it open. We provide the first proof-of-concept of this approach by predicting and crystallizing TcDHODH in complex with an OF inducer, thereby obtaining the OF a priori with its subsequent use in designing potent and selective inhibitors. Fourteen cocrystal structures of TcDHODH with the designed inhibitors are presented herein. This approach has potential to encourage drug design against diseases where the molecular targets are such difficult proteins possessing small AS volume. This approach can be extended to study open/close conformation of proteins in general, the identification of allosteric pockets and inhibitors for other drug targets where conventional drug design approaches are not applicable, as well as the effective exploitation of the increasing number of protein structures deposited in Protein Data Bank.
Introduction
Pyrimidine nucleotides are DNA and RNA building blocks derived from de novo biosynthesis and/or salvage pathways. In humans, both pathways are functional and disruption of one can result in compensation by the other [1] . However, rapidly proliferating cells, including cancer cells or activated lymphocytes, rely on de novo biosynthesis for their growth [2] . Therefore, drugs targeting de novo biosynthesis, N-(phosphonacetyl)-L-aspartate (PALA) and leflunomide (Arava1, Sanofi-Aventis), have anti-cancer and immunosuppressive activities [3] , [2] , respectively. PALA and A771726 (the active metabolite of leflunomide) inhibit the second (aspartate carbamoyltransferase) and fourth (dihydroorotate dehydrogenase, DHODH) steps in de novo biosynthesis, respectively.
In many pathogens, such as Plasmodium falciparum and Helicobacter pylori, the enzymes required for the salvage pathway are missing from their genomes [4] , [5] , making them dependent on de novo biosynthesis. Among Trypanosomatid parasites, Trypanosoma cruzi, the pathogen of Chagas disease, is the only example which relies on pyrimidine de novo biosynthesis. Unlike T. brucei and Leishmania spp. (causative agents of human African trypanosomiasis and leishmaniasis, respectively), the intracellular stage of T. cruzi lacks uracil phosphoribosyltransferase enzymatic activity [6] . Additionally, another key enzyme in the pyrimidine salvage pathway (uridine kinase) is missing from the T. cruzi genome [7] . Consequently, pyrimidine de novo biosynthesis is not essential for T. brucei [8] , [9] , [10] and L. donovani [11] growth, while T. cruzi strictly depends on it [12] , [13] . Therefore, de novo pyrimidine biosynthesis is an attractive target for the development of new drugs to combat Chagas disease.
Among the six steps required for de novo biosynthesis, the fourth step is catalyzed by dihydroorotate dehydrogenase (DHODH) and is a promising drug target because of its diversity. DHODHs are classified into two families according to cellular localization and electron acceptor. Family 1 DHODHs are cytosolic enzymes found in gram-positive bacteria, archaea, and lower eukaryotes. They are further subdivided into family 1A, a homodimeric FMN-containing enzyme using fumarate as an electron acceptor, and family 1B, a heterotetrameric enzyme containing FMN, FAD, and [2Fe-2S] cluster and using NAD + as an electron acceptor. Family 2 DHODHs are found in gram-negative bacteria and eukaryotes, and are localized in the plasma membrane (bacteria) or mitochondrial inner membrane (eukaryotes). They are monomeric/homodimeric enzymes containing FMN and utilize respiratory quinones as electron acceptors [14] . The fact that family 1A DHODH is not connected to the respiratory chain allows some organisms having this class of enzyme, such as Trypanosomatid parasites, being able to biosynthesize pyrimidine even in the hypoxic microenvironment [15] . T. cruzi DHODH (TcDHODH) belongs to family 1A and by using structures complexed with substrates and products, we previously showed that the enzyme utilizes the same site for the firsthalf (dihydroorotate oxidation) and second-half (fumarate reduction) reactions [16] , while family 1B [17] and 2 [18] utilize distinct sites for these reactions. However, there are no reports of a potent, specific inhibitors targeting family 1A DHODHs to date. Respiratory chain (RC) enzymes are promising drug targets because of their wide diversity among species. For example, the RC of blood stream forms of T. brucei possesses trypanosome alternative oxidase (TAO), a membrane associated diiron protein that functions as the sole terminal oxidase, which is absent in human [19] . Potent inhibitor of TAO, ascofuranone (AF), has strong trypanocidal activity in vitro and in vivo [20] , [21] , [22] . Another example is an anaerobic RC of the helminthes. The RC of adult Ascaris suum and Echinococcus multilocularis protoscoleces, contain an anaerobic NADH-fumarate reductase (NADH-FRD) system composed of Complex I (NADH dehydrogenase) [23] , low potential quinone species (rhodoquinone) and Complex II catalyzing the reverse reaction [quinol:fumarate reductase (QFR) [24] , [25] ]. Inhibitors of Complex I have been shown to kill E. multilocularis protoscoleces in vitro, thus chemically validating the NADH-FRD system as a drug target [25] . We have also discovered atpenin A5 as the most potent inhibitor of respiratory Complex II which was later found to inhibit not only eukaryotic but bacterial enzyme as well [26] . Previously, we reported the crystal structures of TAO in complex with ascofuranone derivatives (3VVA and 3W54) [27] as well as A. suum QFR in complex with flutolanil (3VR9 and 3VRB) [28] , [29] , [30] , its derivatives (4YSZ, 4YT0, 4YTM, 4YSX and 4YSY) and the substrate rhodoquinone (5C2T) [31] , providing structural insights into their inhibition mechanisms. Both type of inhibitors bind to the quinol binding site of each target. Because family 2 DHODHs directly link pyrimidine de novo biosynthesis to the RC, structure-based drug-design (SBDD) targeting the ubiquinone binding sites of human [32] , [33] , [34] and P. falciparum [35] , [36] , [37] , [38] DHODHs have been extensively studied, and species-selective DHODH inhibitors were rationally designed. However, these inhibitors target the ubiquinone binding site of only family 2 enzymes and have no obvious effect on family 1A DHODHs since the later lacks the ubiquinone binding site. Because of differences in ubiquinone dependency between human and T. cruzi DHODHs, the main focus of this study was the design of potent and selective inhibitors targeting the family 1A enzyme TcDHODH.
The continuing discovery, in random screening studies, of potent inhibitors that bind and expand the volume (open form, OF) of the target molecule active site emphasizes the importance of the target protein OF structure in drug discovery [39] . However, all targetable OF structures reported to date were obtained a posteriori to the discovered inhibitors. Specifically, they were unexpectedly found binding to the OF after determination of target/inhibitor cocrystal structures. Thus, we hypothesized that obtaining the OF structure of a target protein a priori will enable the design of potent inhibitors using conventional approaches. However, the lack of tools and reports where the OF structure of a target protein was rationally obtained a priori have substantially delayed structure based drug design (SBDD) targeting TcDHODH.
In this study, the "OF inducer" approach was developed in order to obtain the OF structure of TcDHODH a priori. Here, the OF inducer was designed and co-crystallized with TcDHODH. As expected, the structure of TcDHODH with an OF active site was successfully determined. The OF structure was subsequently used to design and synthesize several potent and selective inhibitors. From the 13 orotate derivatives designed in this study, the co-crystal structures of TcDHODH in complex with all derivatives were obtained. This allowed us to validate the OF inducer approach as a novel and powerful tool to understand the OF structures and consequently enabling the design of potent and specific inhibitors.
Material and Methods

Enzyme assays
The enzyme activity of TcDHODH was assayed spectrophotometrically by monitoring the direct production of orotate at 290 nm. The TcDHODH standard assay (TSA) solution contained 100 mM sodium phosphate buffer (pH 8.0), 2 mM fumarate, and 1 μg/ml of TcDHODH. Equal volumes (2 μl) of an inhibitor dilutions series (11 wells for inhibitor plus 1 for DMSO control) were transferred to a 96 well plate with UV transparent flat bottom (Corning Inc.) followed by 188 μl of TSA solution. To assess background activity, the plate was placed in a SpectraMax M2e-TUY plate reader (Molecular Devices), mixed for 5 seconds before the first read (kinetic mode) and 3 seconds between reads during the 5 minute assay. The reaction was started by quickly adding 10 μl of 10 mM L-dihydroorotate stock solution (final concentration of 500 μM) and TcDHODH activity was assayed with the same parameters used in the background assay. The rate (Abs/min) during the first 2 minutes was calculated using SoftMax Pro 5.3 software (Molecular Devices). The rate relative to DMSO control (100%) versus inhibitor concentration was plotted and IC 50 values calculated as the concentration of inhibitor that produces a 50% reduction in relative enzymatic activity. For HsDHODH, the standard assay (HSA) mixture contained 100 mM HEPES (pH 8.0), 150 mM NaCl, 5% (v/v) glycerol, 0.05% (w/v) Triton X-100, 200 μM L-dihydroorotate, 120 μM 2,6-dichloroindophenol (DCIP), and 14 μM decylubiquinone (dUQ). A reaction start (RS) solution was prepared, containing 40 μg/ml HsDHODH (specific activity of 50 μmol/min/mg) in 100 mM HEPES (pH 8.0), 250 mM NaCl, 5% (v/v) glycerol, and 0.05% (w/v) Triton X-100. Ten microliter of inhibitor dilution series were transferred to a 96 well plate (Nunc) and mixed with 185 μl of HSA. The plate was vortexed for 20 seconds and the background recorded for 5 min at 600 nm. The reaction was started by adding 5 μl of RS solution, vortexing for 20 seconds, and HsDHODH activity assayed using the end point method after 20 minutes with a SpectraMax M2e-TUY plate reader (Molecular Devices) and analyzed using SoftMax Pro 5.3 software (Molecular Devices). The amount of DCIP reduced in the presence of DMSO was set to 100%, the relative activity versus inhibitor concentration was plotted and the IC 50 values calculated. Each data point was assayed in triplicate on the same day. K i app values were calculated using the Cheng-Prusoff equation with a K m for dUQ of 14.0 μM and for dihydroorotate of 25.9 μM as previous described, for HsDHODH [33] and TcDHODH [15] , respectively.
Size exclusion chromatography
The size of TcDHODH was estimated by HPLC using a TSK gel G3000SW (Tosoh) column (7.5 × 600 mm), as previously described [15] , [16] . Purified TcDHODH (0.5 mg) was mixed with 50 μl of Gel Filtration Standard (Bio-Rad) and injected to the column. The analysis was performed at room temperature with a flow rate of 1 ml/min in 100 mM sodium phosphate buffer (pH 7.5) containing 500 mM NaCl and 0.25 mM sodium orotate. The molecular weight of TcDHODH was calculated as 37 kDa based on the retention times of proteins in the Gel Filtration Standard (Bio-Rad).
DHODH activity staining
Blue native PAGE (BN-PAGE) of TcDHODH was performed according to the manufacturer's instructions. 1250 to 20 ng of pure TcDHODH in 5% (v/v) glycerol and 0.01% (w/v) Ponceau S was loaded onto a 4-16% (w/v) Bis-Tris gel (Invitrogen) and run at 150 V using the light blue cathode buffer method [0.002% (w/v) of G-250 blue dye] at 4˚C. Electrophoresis was terminated when the Ponceau S band reached approximately 1 cm from the bottom of the gel. The gel was transferred to a container, washed three times with 5 mM Tris-HCl pH 7.4 and incubated with 5 mM Tris-HCl pH 7.4 containing 2.5 mg/ml nitro blue tetrazolium chloride. The TcDHODH band was stained with L-dihydroorotate (0.25 mM) without phenazine methosulfate (PMS) at room temperature. A dark purple band corresponding to TcDHODH appeared within 5 seconds in the lane containing 1250 ng and within 2 minutes in the lane containing 20 ng. Since HsDHODH is a membrane protein and requires Triton X-100, highresolution clear native electrophoresis was chosen for DHODH activity staining. Purified HsDHODH (1250 to 50 ng) was loaded onto 4-16% (w/v) Bis-Tris gel (Invitrogen) and run at 150 V at 4˚C, according to the manufacturer's instructions. HsDHODH activity was stained as described for TcDHODH, however in the presence of 0.06 mg/ml PMS. After DHODH activity staining, the gels were extensively washed with water and the molecular weight marker (NativeMark TM Unstained Protein Standard, BioRad) was stained with GelCode1 Blue Stain Reagent (Pierce). The molecular weight of TcDHODH and HsDHODH was calculated by constructing a Ferguson plot [40] using the NativeMark TM standards.
Assessment of steric repulsion between 5-substituted orotate and the active site loop moiety
To obtain a crystal structure with open loop conformation, steric repulsion between substituents (R-groups) at the 5-position of orotate and the active site loop (L128-Q138) of the closed form of TcDHODH were assessed. Firstly, nine orotate derivatives with different sized 5-substituents were prepared in silico. The conformational searches of the nine derivatives were performed using the modeling software MOE 2007.09 [41] , with MMFF94x force field, and stable conformers (ΔE 5 kcal/mol) for each compound were selected. The generated conformers were superposed with orotate on the closed form of TcDHODH. Using the superposed models, van der Waals volumes shared between a substituent at the 5-position of orotate and the active site loop was calculated for each conformer. Fig 1A shows the distribution of the calculated shared volumes of the orotate derivatives. To stably change the conformation of the loop, propyl, 3,3-dimethylbuthyl, and ethylbenzene groups were predicted to have sufficient sizes compared with those of halogen, methyl, and ethyl groups. Orotate derivative containing 3,3-dimethylbuthyl was selected as the first OF inducer and its binding mode confirmed by co-crystallographic study.
Design of the 5-substituted orotate library based on the open form of TcDHODH
From the analysis of ligand contact preference around the orotate binding site according to the modeling software MOE [41] , the binding region around the 5-position of orotate was predicted to preferably interact with hydrophobic ligand atoms. In fact, the region is surrounded by the hydrophobic amino acid residues L71, L101, and P131. Across the hydrophobic region, there are H-bonding sites, such as N53 and R50, which are accessible with substituents at the 5-position of orotate. To improve potency of orotate derivatives by interacting with the predicted pharmacophore features, we designed a 5-substituted orotate library. 5-Substituted The graph was generated using coordinates from the TcDHODH-orotate complex structure (2E6A) [16] and calculated using MOE [41] . (B) Superposition of various conformations of 1 generated by MOE [41] to the active site of the TcDHODH-orotate complex structure. FMN and TcDHODH are shown in green as stick and ribbon, respectively. The active site loop and C130 are shown in orange. 2 /C [20% (w/w)] was added to a solution of the crude alkyne in MeOH/AcOH (9:1, 10 mL). After stirring under H 2 atmosphere at room temperature for 12 h, the mixture was filtrated through a celite pad. The residue was washed with MeOH and dried in vacuo to afford crude methyl ester, which was used in the next reaction without further purification.
1 M NaOH aq (0.1 mL) was added to a suspension of the crude methyl ester in EtOH (1 mL) at room temperature. After stirring at 50˚C for 6 h, the solvent was evaporated. The resulting solid was dissolved in monoethanolamine-AcOH (pH 9) buffer and purified with HPLC (monoethanolamine-AcOH (pH 9) buffer/CH 3 CN) to afford the orotic acid derivatives as monoethanolamine salts.
Crystallization
TcDHODH was expressed, purified, and crystallized essentially according to the methods described previously by Inaoka [44] , [16] . Co-crystal structures of TcDHODH with 5-substituted orotate derivatives were prepared by initial soaking of TcDHODH-oxonate crystals in a fresh reservoir solution containing 0.05 mM 5-substituted orotate derivatives (soaking solution) and then gradually increasing its concentration every 12 hours, up to 0.2~5 mM.
Data collection
The Table] . All the data sets were processed and scaled with HKL2000 [45] .
Refinement
The crystal structure of TcDHODH in complex with compound 1 was solved by molecular replacement using the coordinates from TcDHODH-oxonate (2E6F) [16] as the search model. For the remaining co-crystal structures of TcDHODH in open form, the coordinates from TcDHODH-compound 1 (3W1Q) was used. Manual building of the remaining model from TcDHODH and further crystallographic refinement were performed with the COOT [46] and REFMAC5 [47] softwares. Data collection and structural refinement statistics are summarized in S1 Table. Figures showing protein structures were prepared with the graphics programs PyMol (http://www.pymol.org/) and MOE [41] .
Results and discussion
Open form inducer design
The small volume of the closed form of TcDHODH impedes the design of nanomolar inhibitors. Therefore, a new approach was developed to obtain the OF a priori for the purpose of designing potent inhibitors. In the ligand-free structure of TcDHODH, the electron density map of the active site loop (L128-D142) is poorly defined, indicating a high degree of flexibility [16] , which is stabilized only by binding of ligands in the active site. We have previously reported that the Sγ atom of C130 in the active site loop, the key residue during catalysis, is located just 3.52 Å away from C5 of the dihydroorotate pyrimidine ring [16] . Because of the close contact with the active site loop, several orotate derivatives containing small substituents at C5 of the pyrimidine ring were analyzed in silico. The degree of steric repulsion with the flexible loop was calculated as the shared volume between C130 and various conformers of 5-substituents (Fig 1A) . Of the 5-substituted derivatives analyzed, the t-butyl-ethyl and phenyl-ethyl groups were predicted to cause higher degrees of steric repulsion than halogen and short alkyl groups (Fig 1A) . Fig 1B shows the calculated alternative conformers of 1, docked into the orotate binding site, causing steric repulsion with C130. To validate the OF inducer approach, 1 was synthesized and evaluated. Despite the low inhibitory activity of 1 (IC 50 ! 400 μM, Table 1 ), the crystal structure of TcDHODH in complex with 1 was successfully prepared by soaking method. After refinement, a clear electron density map corresponding to 1 was readily distinguished from oxonate ( Fig 1C) . As expected, 1 was found binding with its tbutyl-ethyl group replacing the position occupied by Sγ of C130 in the closed form, forcing active site opening (Fig 1C) . Previously, three regions around the active site loop were identified as potential drug-binding sites: the active site (S1), extension of S1 site (S2), and the site behind the active site loop (S3) [48] . The binding of 1 pushed the active site loop to the S2 site; in addition, the S1 and S3 sites become connected by the region previously occupied by the active site loop (S1 Fig). Binding also increased to more open in the active site of chain B than A due to crystallization packing. In chain B, Sγ of C130 moved 8.16 Å while Nδ of N132 moved 17.91 Å (Fig 1C) . Design of potent and selective 5-substituted orotate derivatives 5-Substituted orotate derivatives can be easily synthesized from terminal alkynes (Fig 3) . Using commercially available terminal alkynes, a virtual library containing 2170 orotate derivatives was constructed and docked into the OF TcDHODH (Fig 3) . From the resulting 225 compounds with high docking scores, 4 compounds (2-5) with higher docking scores, predicted to interact with the hydrophobic region, were selected and synthesized (Table 1) . To validate our predictions, the IC 50 and K i app values of 2-5 were analyzed. All 4 compounds were more potent than orotate (Table 1) . In order to determine the selectivity index (SI) of the orotate derivatives, recombinant human DHODH (HsDHODH) was purified and the IC 50 and K i app values determined. 2 did not inhibit HsDHODH at high concentrations (5 mM) and exhibited higher SI (> 814-fold) than 3, 4, and 5 (231, 104, and 284, respectively; Table 1 ). To confirm the structural basis of predicted versus crystallographic inhibitor binding modes and selectivity, the structures of TcDHODH complexed with 2-5 were determined. The binding mode of each derivative was found to be consistent with our docking model (S3 Fig). In the crystal structures, the 5-substituent group of 2-5 (Table 1) interacts through CH-π interactions with P131 at the hydrophobic region, which explains their increased inhibitory potency compared to orotate (S3 Fig). The low K i app (0.22 μM) of 4 is the result of a unique interaction, in which the naphthyl group is sandwiched by CH-π interactions between G70 and P131, which are not observed with compounds 2, 3, and 5 ( S3 Fig). The high selectivity of those compounds against TcDHODH is attributed to the L71 to F149 substitutions in HsDHODH. The bulkier side chain of F149, compared to L71, causes steric repulsion with the 5-substituted group, making binding to HsDHODH unfavorable. From these results we can conclude that the hydrophobic region can be targeted to increase the inhibitory potency as well as to increase the selectivity of these compounds toward TcDHODH. The effect of an additional hydrogen bond in the 5-substituted orotate derivatives was also investigated by introducing methoxy groups at positions 5, 6, and 7 of the naphthyl ring (6, 7, and 8, respectively, Table 1 ). 6 and 7 decreased the by 2-fold (0.11 μM and 0.14 μM, According to our predictions, the methoxy groups on 6, 7, and 8 should form hydrogen bonds with the NH 2 side chain of N53. In fact, a hydrogen bond between the methoxy group and N53 was observed in 7 bound to the A and B chains and in 8 bound to the A chain. However, an unexpected hydrophobic interaction between the methoxy group and the alkyl side chain of K214 was found in 6 (S4 Fig) . This hydrophobic interaction was also seen in the A chain of the TcDHODH-7 co-crystal structure. The comparison of binding modes and K i app (Table 1) between 6 and 7 clearly indicates that the loss of the hydrogen bond with N53 can be compensated with an unusual hydrophobic interaction with the alkyl side chain of nearby K214 without affecting the K i app values. Since the CH-π interaction between P131 and the naphthyl group of 8 was lost (S4 Fig), this may contribute to the slightly higher K i app value of 8 compared to 6 and 7. These results indicate that optimum interaction with K214 and N53 can be achieved by introducing a hydrogen bond acceptor at positions 5 and 6 of the naphthyl group, respectively. In order to strengthen the interaction with K214 and N53, carboxylate groups at positions 5 and 6 (9 and 10, respectively, Table 1 ) of the naphthyl group were introduced. Considering the pK a of 3.69 and 4.17 of 1-and 2-naphthoic acid, respectively [49] , it is expected that the carboxylate groups in 9 and 10 should be present in anionic form during crystallographic studies (pH 5.3). Carboxylate group substitution remarkably decreased the K i app of 9 (0.03 μM) and 10 (0.02 μM). It also increased the K i app for HsDHODH to >2500 and 893 μM for 9 and 10, respectively (Table 1) . Consequently, this dramatically increased the selectivity index against TcDHODH to >75800 and 37200 for 9 and 10, respectively (Table 1) . Since 9 and 10 are the most potent inhibitors of family 1A DHODHs reported, their cocrystal structures in complexes with TcDHODH were obtained and the binding mode was analyzed in detail. Fig 4A shows the binding mode of 9 in the A (left) and B (right) chains of TcDHODH. As expected, the carboxylate group of 9 formed a salt bridge with K214. With 10, the predicted hydrogen bond with N53 in chain A was confirmed by the co-crystal structure (Fig 4B) . Interestingly, 10 was found binding in a dual mode in the B chain ( Fig 4C) ; "7-like" and "non-7-like" binding modes perfectly fit into the density map (Fig 4C) . In 7-like mode, the carboxylate group forms a hydrogen bond with N53 (Fig 4C, left) while in non-7-like mode it forms a salt bridge with K214 and a hydrogen bond with N198 (Fig 4C, right) . The similarity of the B-factors of the non-7-like (9.2) and 7-like (10.2) binding modes of 10 and the protein [B-factors are 9.8 and 11.8 for the A and B chains, respectively (S1 Table) ] indicates Virtual library of 5-substituted orotate derivatives. 5-Substituted orotate derivatives can be synthesized by Sonogashira coupling using terminal alkynes. A virtual library was generated in silico using all 2170 commercially available terminal alkynes, screened against the more OF TcDHODH-1 crystal structure and clustered into groups according to their docking scores. 20 compounds with high docking scores were selected and synthesized.
doi:10.1371/journal.pone.0167078.g003
The Open Form Inducer Approach for Structure-Based Drug Design that both conformations of 10 are stably bound to TcDHODH. Moreover, a cryoprotectant glycerol molecule (GOL410) was found interacting with the naphthyl ring of the non-7-like mode and the O2 orotate pyrimidine ring of 10 (Fig 4C, right) in the B chain. In addition, GOL410 forms hydrogen bonds with the side chain hydroxyl group and main chain oxygen of S195 (Fig 4C, right) . This finding indicates the possibility of developing more potent orotate derivatives using a fragment-based approach, which is now in progress.
Para-alkyl-phenylethyl orotate derivatives as novel Q-site inhibitors of HsDHODH
During the drug-design process, we found that four 5-phenylethyl orotate derivatives containing an alkylated substitution at the para position of the phenyl ring (11-14, Table 1 ) exhibited increased inhibition of HsDHODH (Table 1) . Co-crystal structures show that 11-14 bind to the TcDHODH OF and interact with the hydrophobic region, as expected (Fig 5A to 5D) . Because of the L71 to F149 substitution in HsDHODH, 11-14 were not predicted to inhibit The Open Form Inducer Approach for Structure-Based Drug Design
HsDHODH. However, all four compounds showed remarkably decreased K i app against
HsDHODH. In particular, 14 shows a K i app of 0.485 μM for HsDHODH and a very poor selectivity index (0.61). As a positive control for HsDHODH assays, the active metabolite of leflunomide, A771726, exhibited an IC 50 of 0.38 μM (K i app = 0.19 μM) in our assay conditions, consistent with the reported K i value of 0.18 μM [50] . To understand the structural basis of HsDHODH inhibition by 11-14, we obtained the co-crystal structure of 14 with HsDHODH and compared it to that of TcDHODH (S2 Table) . Surprisingly, 14 did not bind to the orotate binding site. Instead, it was bound to the hydrophobic tunnel involved in the binding of ubiquinone (Q-site) at the N-terminal region (Fig 6A) , which is absent in TcDHODH.
Brequinar is a competitive inhibitor versus ubiquinone [51] for rat DHODH and the crystal structure of a brequinar analog-HsDHODH complex (Fig 6A) is available (1D3G) [18] . Comparison of crystal structures of HsDHODH in complex with 14 ( Fig 6A, right) and a brequinar analog (Fig 6A, left) clearly shows that the binding sites of these inhibitors completely overlap (Fig 6B, left and Fig 6C, right) . Interestingly, 14 bound the Q-site in dual mode, which are brequinar-like (Fig 6B, right) and non-brequinar-like (Fig 6C, left) . In brequinar-like mode, the carboxylate group of 14 interacts with R136 (Fig 6A, right) , while interacting with Y356 in non-brequinar-like mode (Fig 6B, left) . This versatile property of the Q-site of HsDHODH, allowing binding of different conformations of carboxylated inhibitors, is consistent with the observations of Baungartner and colleagues [34] . Because of the structural similarity of 11-14, we can conclude that the decreased specificity is the result of binding at the Q-site and not to the orotate binding site of HsDHODH.
Correlation between docking scores and IC 50 Finally, correlation analysis between in silico and inhibition studies of all 5-substituted orotate derivatives was performed ( S5 Fig). The result clearly show that a good correlation between calculated docking scores and experimentally determined IC 50 s for all compounds designed in this study, thus validating our drug design methodology.
Conclusion
This study provides the first proof-of-concept for a rational determination of protein OF conformations a priori using the OF inducer approach, specifically for proteins containing flexible regions around their active site. We also show that determination of the OF structure at the early stage of SBDD constitutes a shortcut for obtaining nanomolar inhibitors.
The X-ray analyses of ligand-free TcDHODH structures, as well as in complex with ligands, show that the L128-D142 loop functions as a lid, completely covering the active site (closed form). In silico screening based on the active site structure in the closed form failed to identify lead compounds that inhibit TcDHODH more potently than orotate (unpublished results). To explain this, a histogram correlating the inhibitor binding site volume versus IC 50 was generated using over 3125 inhibitor-target complexes with known IC 50 s (from PDBbind). Binding site volumes > 400 Å 3 are necessary to design inhibitors with nanomolar IC 50 values (Fig 7) . Successful examples of SBDD targeting protein-protein interaction (PPI) sites (ex. Bcl-2 family proteins) [52] , [53] , [23] , allosteric sites (ex. G-protein-coupled receptor) [54] , or active sites (ex. human and P. falciparum DHODHs) [33] , [55] have been reported. The crucial prerequisite for targeting PPI sites is the necessity of protein subunit association for biological function in the target protein. Enzymes belonging to family 1A are homodimeric and inhibitors targeting the interface between monomers may be attractive sites for drug design. However, evidence from size-exclusion chromatography, activity staining and dynamic light scattering indicate that the PPI approach was not applicable to TcDHODH, which functions in monomeric form and becomes homodimeric at high concentrations only (S6 and S7 Figs and S3 Table) .
Difficulties in obtaining the OF structure of a target protein with the small volume of a drug binding pocket, are common problems encountered during drug-design. In this study we show that TcDHODH has a small active site and is the first monomeric enzyme among reported family 1A DHODHs. From a practical standpoint, conventional approaches for drug design were not applicable for TcDHODH. We have previously reported that TcDHODH contains a highly flexible active site loop composed of residues from L128 to D142, as demonstrated by the ligand-free structure [16] . Additionally, the co-crystal structures with different ligands could be easily obtained by soaking method. This has made TcDHODH an ideal model to design potent inhibitors using the OF inducer approach.
Because of the high conservation of residues forming the small active site pocket among T. cruzi and human DHODHs, the design of a specific and potent inhibitor was difficult. Using the OF inducer approach, we obtained the OF structure of TcDHODH and showed that many residues surrounding the active site are specific for TcDHODH. By targeting the active site structure with OF, we show the first successful demonstration of the design of potent and selective inhibitors of a family 1A DHODH. The OF inducer approach will contribute to the development of new drugs against Chagas disease, and represents a powerful new tool for drug design. This approach has potential to encourage drug design against diseases where the molecular targets are such difficult proteins possessing small AS volume. The size of TcDHODH was estimated using TSK G3000SW (Tosoh) gel filtration column (7.5 × 600 mm). Purified TcDHODH was mixed with 50 ml Gel Filtration Standard (Bio-Rad) to a final concentration of 0.5 mg/ml and injected to the column. The analysis was performed at room temperature at flow rate of 1 ml/ min in 100 mM sodium phosphate buffer pH 7.5, 150 mM NaCl and 0.25 mM sodium orotate. 
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